<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KNJ24DXQ" height="0" width="0" style="display:none;visibility:hidden"></iframe>
Dr. Defeng ZHAO

Dr. Defeng ZHAO

  • Associate Chief Physician
  • Director, Ward 6, Department of Hematology I (Hematology/Oncology), Beijing GoBroad Boren Hospital
Request an Appointment

About the Doctor

Dr. Defeng Zhao has more than 20 years of clinical experience in hematology and is highly skilled in managing complex and critically ill hematologic patients. After graduating from the Second Military Medical University, he has focused extensively on the diagnosis, treatment, and long-term management of acute and chronic leukemias, lymphomas, multiple myeloma, and other hematologic malignancies. He has substantial expertise in clinical assessment, treatment integration, and complication management for diverse blood disorders.

In the field of hematologic malignancies, Dr. Zhao has in-depth experience with CAR-T cell therapy and immune-targeted therapies. He excels in developing CAR-T therapeutic strategies, managing treatment-related toxicities (including CRS/ICANS), and conducting post-treatment monitoring for leukemia, lymphoma, and multiple myeloma. For patients with relapsed or refractory disease, he specializes in creating precise, individualized treatment plans tailored to disease biology, significantly improving patient outcomes. Dr. Zhao is also actively engaged in clinical research, and his work has been presented multiple times at major international hematology conferences, demonstrating his continuous contribution to cutting-edge clinical practice. He closely follows global developments in hematology and incorporates the latest evidence-based advances into his clinical decision-making, ensuring that patients receive safe, scientific, and state-of-the-art care.

Areas of Expertise

  • Comprehensive management of leukemia, lymphoma, and multiple myeloma
  • CAR-T cell therapy (patient evaluation, treatment implementation, CRS/ICANS management, and long-term monitoring)
  • Precision treatment planning integrating immunotherapy and targeted therapy with chemotherapy
  • Salvage strategies for relapsed/refractory hematologic malignancies
  • Multidisciplinary management (MDT) of complex hematologic diseases

Contact information and location

Whatsapp
+86 15901185120
Address
Block A/B/C,Longwei Square,Jitong East Road,Fengtai District,Beijing,China

Related reading

VARELII, Russian, Acute B-cell lymphoblastic leukemia

VARELII is an acute B-lymphoblastic leukemia patient from Russia. The news of a relapse after his second transplant left him in despair for a while, and the local hospital in Russia thought he had almost no chance of being cured.

But VARELII didn't give up, through many aspects of understanding and research, he contacted the team of Director Zhao Defeng of Beijing GoBroad Boren Hospital, who accepted VARELII after sufficient communication and comprehensive evaluation in the early stage. I thought I would be rejected for admission, but the team of Director Zhao accepted me and gave me the motivation to have a positive treatment. With the last glimmer of hope, accompanied by his wife, VARELII traveled thousands of miles to receive CAR-T treatment.

After VARELII came to Boren Hospital, he first received a comprehensive examination and test. After the test, it was found that there was not only bone marrow recurrence, but also tumor cells in the cerebrospinal fluid, which was actually a state of bone marrow recurrence combined with central recurrence, and the condition was very critical. Moreover, the gene BCR-ABL1 was found in this examination, which was not found at the onset of the patient's disease. Boren Hospital has laid a solid foundation for the patient's personalized treatment plan by integrating the diagnosis through precise genetic testing.

The patient came in very weak, with anemia, low platelets, and high tumor load, plus having already undergone two transplants, he was under tremendous stress, both physically and psychologically. Director Zhao Defeng's team first communicated with the patient, indicating that there was hope that the disease could reach remission through CAR-T cell therapy. The team gave the patient confidence in the treatment and then formulated a personalized treatment plan based on the patient's status.

The medical team chose the first target to use donor-sourced cells to prepare CD19 CAR-T cells for treatment, and the overall infusion back process was relatively smooth, although there was still cytokine release syndrome (CRS), with symptoms of fever and rash, but with the medication, the side-effects were quickly and effectively controlled.

 After the second relapse in Russia, my heart was very heavy, through this period of treatment and communication with Director Zhao's team, my confidence was slowly restored, and the actual treatment effect was also very good, thanks to all those who helped me, so that a person who had lost hope, had the hope to live again. VARELII said.

 Before being discharged from the hospital, VARELII's bone puncture results showed that his bone marrow had reached deep remission, with a gene of 0. The lumbar puncture results showed that the tumor cells in the cerebrospinal fluid had also dissipated, and the white blood cells, red blood cells, and platelets had basically returned to normal, with the disease reaching a very good state of complete remission.

In order to show their gratitude, VARELII and his wife specially customized a silk banner and personally gave it to Director Zhao Defeng's team before they were discharged from the hospital, The whole treatment process moved me a lot, thanks to Boren Hospital and Director Zhao's team, which enabled me to start working and living again, and I hope that I can bring my family to China for a trip next time, instead of treating the disease any more! VARELII is looking forward to the future.

View

We're here for you.

Get in touch.

We're here to make sure you are connected to the right people.

Request an Appointment